RT Journal Article
SR Electronic
T1 Valence-dependent self-agency is disturbed in depression and anxiety
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.11.22277423
DO 10.1101/2022.07.11.22277423
A1 Mehta, Marishka M
A1 Na, Soojung
A1 Gu, Xiaosi
A1 Murrough, James W
A1 Morris, Laurel S
YR 2022
UL http://medrxiv.org/content/early/2022/07/12/2022.07.11.22277423.abstract
AB Background The sense of agency, or the belief in action causality, is an elusive construct that impacts day-to-day experience and decision-making. Despite its relevance in a range of neuropsychiatric disorders, it is widely under-studied and remains difficult to measure objectively in patient populations. We developed and tested a novel cognitive measure of valence-modulated agency perception in an in-person and online cohort.Methods The in-person cohort consisted of 52 healthy control subjects and 20 subjects with depression and anxiety disorders (DA), including major depressive disorder and generalized anxiety disorder. The online sample consisted of 254 participants. The task consisted of an effort task for monetary rewards with computerized visual feedback interference and trial-by-trial ratings of self versus other agency.Results All subjects across both cohorts demonstrated higher self-agency after receiving positive-win feedback, compared to negative-loss feedback when the level of computer inference was kept constant. Patients with DA showed reduced positive valence-dependent agency compared to healthy controls. Finally, in both cohorts, lower self-agency following negative-loss feedback was associated with worse anhedonia symptoms.Conclusion Together this work suggests how positive and negative environmental information impacts the sense of self-agency in healthy subjects, and how it is perturbed in patients with depression and anxiety.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by NIMH/K01MH120433 for LSM. Additional funding was provided by the Ehrenkranz Laboratory for Human Resilience and the Friedman Brain Institute, both components of the Icahn School of Medicine at Mount Sinai. XG is supported by National Institute of Mental Health [grant number: R21MH120789, R01MH122611, R01MH123069].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Program for Protection of Human Subjects (PPHS)/Institutional Review Board (IRB) at Icahn School of Medicine at Mount Sinai gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors